To advance the call to action to optimize dosage of anticancer agents, FDA and ASCO cosponsored two multistakeholder workshops, Getting the Dose Right: Optimizing Dose Selection Strategies in Oncology ...

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas ...

We aimed to assess whether lung cancer (LC) screening with low-dose computed tomography (LDCT) is cost effective in a high-risk population (current or former smokers—who stopped smoking within <15 ...

In the article that accompanies this editorial, Yin et al 12 present the early phase development and validation of a fragmentomics-based biomarker for the earlier detection of pancreatic cancer. While ...

Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the ...

In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma" by ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

PURPOSEThe surveillance protocol for early-stage non–small cell lung cancer (NSCLC) is not contingent upon individualized risk factors for recurrence. This study aimed to use comprehensive data from ...

Low-dose radiation demonstrates efficacy in treating primary cutaneous T-cell lymphomas. This study evaluated the safety and efficacy of low-dose total skin electron beam therapy (TSEBT) regimens in ...

Liability Risks of Ambient Clinical Workflows With Artificial Intelligence for Clinicians, Hospitals, and Manufacturers ...

Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was ...

As an oncologist trained in a program with a strong emphasis on shared decision making between physician and patient, I approach such situations with curiosity. I consider optimal shared decision ...